CEMP: Stock Quote & Summary Data |
Company Description (as filed with the SEC)
We are a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of infectious diseases, particularly respiratory tract infections and chronic and acute staphylococcal infections. Our lead program, CEM-101, which we are developing in both oral and intravenous, or IV, formulations initially for the treatment of community acquired bacterial pneumonia, or CABP, one of the most serious infections of the respiratory tract, recently completed a successful Phase 2 clinical trial of the oral formulation for the treatment of CABP, demonstrating comparable efficacy to the current standard of care, levofloxacin, with a favorable safety and tolerability profile. Our second program is Taksta, which we are developing in the U.S. as an oral treatment for bacterial infections caused by S. ... More ...
Links to all Cempra, Inc. (CEMP) Pages
Stock Analysis
Fundamentals
Holdings
/Ownership
Consensus Recommendation |
|
Analyst Info |
|
| Annual EPS Est: | $-47.53 |
| Quarterly EPS Est: | -0.21 |
| PEG Ratio: | -.01 |
| Mean Recommendation: View Summary/View All |
1.25 |
Data is provided by Zacks Investment Research
Home
Search NASDAQ
Search Web

Symbol List Views
Stock Details
CHARTS
COMPANY NEWS
STOCK ANALYSIS
FUNDAMENTALS
HOLDINGS
